CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 110, Issue 27, Pages 11091-11096
Publisher
Proceedings of the National Academy of Sciences
Online
2013-06-18
DOI
10.1073/pnas.1222251110
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NT5E CpG island methylation is a favourable breast cancer biomarker
- (2012) C Lo Nigro et al. BRITISH JOURNAL OF CANCER
- CD73-Deficient Mice Are Resistant to Carcinogenesis
- (2012) J. Stagg et al. CANCER RESEARCH
- Dissecting the Heterogeneity of Triple-Negative Breast Cancer
- (2012) Otto Metzger-Filho et al. JOURNAL OF CLINICAL ONCOLOGY
- TBCRC 001: Randomized Phase II Study of Cetuximab in Combination With Carboplatin in Stage IV Triple-Negative Breast Cancer
- (2012) Lisa A. Carey et al. JOURNAL OF CLINICAL ONCOLOGY
- A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes
- (2012) Benjamin Haibe-Kains et al. JNCI-Journal of the National Cancer Institute
- The secret ally: immunostimulation by anticancer drugs
- (2012) Lorenzo Galluzzi et al. NATURE REVIEWS DRUG DISCOVERY
- CD73: a potent suppressor of antitumor immune responses
- (2012) Paul. A. Beavis et al. TRENDS IN IMMUNOLOGY
- CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death
- (2011) S. Serra et al. BLOOD
- Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
- (2011) S. R. Mattarollo et al. CANCER RESEARCH
- CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
- (2011) J. Stagg et al. CANCER RESEARCH
- Molecular heterogeneity of triple-negative breast cancer and its clinical implications
- (2011) Sheeba Irshad et al. CURRENT OPINION IN ONCOLOGY
- Altered purinergic signaling in CD73-deficient mice inhibits tumor progression
- (2011) Gennady G. Yegutkin et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice
- (2011) Long Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Multifactorial Approach to Predicting Resistance to Anthracyclines
- (2011) Christine Desmedt et al. JOURNAL OF CLINICAL ONCOLOGY
- Contribution of IL-17–producing γδ T cells to the efficacy of anticancer chemotherapy
- (2011) Yuting Ma et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Directed Therapy of Subtypes of Triple-Negative Breast Cancer
- (2011) L. A. Carey ONCOLOGIST
- Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
- (2011) M. Michaud et al. SCIENCE
- Triple-Negative Breast Cancer
- (2010) William D. Foulkes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Extracellular adenosine triphosphate and adenosine in cancer
- (2010) J Stagg et al. ONCOGENE
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
- (2010) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
- (2009) François Ghiringhelli et al. NATURE MEDICINE
- Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes
- (2008) C. Desmedt et al. CLINICAL CANCER RESEARCH
- The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferation
- (2008) Luci Bavaresco et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started